Summary
BeOne Medicines Ltd. (ONC), a biotechnology company, is filing an 8-K to address a notice from The NASDAQ Stock Market (NASDAQ) regarding a potential non-compliance with listing rules. The issue stems from the departure of Ke Tang, a member of the Company's Audit Committee, who did not stand for re-election. This departure has temporarily caused BeOne Medicines to fall below NASDAQ's audit committee composition requirements under Listing Rule 5605. The company has promptly notified NASDAQ of Mr. Tang's departure and is actively working to rectify the situation. BeOne Medicines intends to appoint a new director to fulfill the audit committee requirements within the stipulated 'cure period' provided by NASDAQ. This period extends to the earlier of their next annual shareholders' meeting or June 1, 2018, with a potential earlier deadline if the next annual meeting is held before November 28, 2017. Investors should monitor the company's progress in appointing a new audit committee member to ensure continued listing on NASDAQ.
Key Highlights
- 1BeOne Medicines Ltd. received notification from NASDAQ that it is currently non-compliant with audit committee composition requirements.
- 2The non-compliance is due to the departure of Audit Committee member Ke Tang, who did not seek re-election.
- 3The company has notified NASDAQ of the situation and is committed to resolving it.
- 4BeOne Medicines plans to appoint a new director to meet NASDAQ's audit committee requirements.
- 5A 'cure period' has been granted by NASDAQ to allow the company to regain compliance, with a deadline of the earlier of the next annual shareholders' meeting or June 1, 2018.
- 6The company is an 'emerging growth company' and has elected to use the extended transition period for new accounting standards.